ARCA biopharma (NASDAQ:ABIO) is up 58% premarket after announcing a
new development program to evaluate AB201 (rNAPc2), a potent, selective
inhibitor of tissue factor, as a potential treatment for COVID-19
associated coagulopathy, a condition characterized by abnormal blood
clotting and the related inflammatory response.
AB201 has previously undergone clinical testing
through Phase 1 and 2 in more than 700 patients for other indications,
generating substantial safety data, which may enable more rapid
development.
ARCA anticipates IND filing in Q3 and initiating late-stage clinical testing in H2.
Prior rNAPc2 results treating Ebola and Marburg
viral infections in non-human primate trials support development as
treatment for RNA virus associated disease.
https://seekingalpha.com/news/3578230-arca-bio-up-on-ab201-program-for-covidminus-19-related-coagulopathy
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.